Jingda Biotechnology

Jingda Biotechnology is an innovative Chinese biopharmaceutical company focused on the development of universal natural killer (NK) and CAR-NK cell therapies for the treatment of hematological and solid tumors. Established in 2015 and based in Beijing’s Daxing District, the company leverages a full-process R&D platform that integrates NK cell screening, virus transduction, and large-scale expansion. Its lead programs include JD001, a CAR-NK therapy targeting CD19 for chronic lymphocytic leukemia, and AMUN-003, an oncolytic adenovirus designed to modulate the tumor microenvironment in triple-negative breast cancer. Jingda aims to provide high-quality, cost-effective 'off-the-shelf' cell drugs through its proprietary manufacturing and technology suites. The company has attracted investments from specialized venture capital firms such as Jinke Junchuang Capital to support its pipeline of gene and cell therapy products.